📣 VC round data is live. Check it out!

MiMedx Group Valuation Multiples

Discover MiMedx Group's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like IBA Group, Nika Pharmaceuticals, Ironwood Pharmaceuticals, XOMA Royalty and more.

MiMedx Group Overview

About MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.


Founded

2008

HQ

United States

Employees

837

Website

mimedx.com

Financials (LTM)

Revenue: $355M
EBITDA: $61M

EV

$390M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

MiMedx Group Financials

MiMedx Group reported last 12-month revenue of $355M and EBITDA of $61M.

In the same LTM period, MiMedx Group generated $284M in gross profit, $61M in EBITDA, and $24M in net income.

Revenue (LTM)


MiMedx Group P&L

In the most recent fiscal year, MiMedx Group reported revenue of $419M and EBITDA of $105M.

MiMedx Group is profitable as of last fiscal year, with gross margin of 83%, EBITDA margin of 25%, and net margin of 12%.

See analyst estimates for MiMedx Group
LTMLast FY202320242025202620272028
Revenue$355M$419M$321M$349M$419M
Gross Profit$284M$346M$267M$289M$346M
Gross Margin80%83%83%83%83%
EBITDA$61M$105M$41M$64M$79M
EBITDA Margin17%25%13%18%19%
EBIT Margin10%19%12%17%15%
Net Profit$24M$49M$67M$42M$49M
Net Margin7%12%21%12%12%

Financial data powered by Morningstar, Inc.

MiMedx Group Stock Performance

MiMedx Group has current market cap of $532M, and enterprise value of $390M.

Market Cap Evolution


MiMedx Group's stock price is $3.57.

MiMedx Group share price decreased by 3.0% in the last 30 days, and by 41.5% in the last year.

MiMedx Group has an EPS (earnings per share) of $0.33.

See more trading valuation data for MiMedx Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$390M$532M-0.3%-3.0%-9.6%-41.5%$0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

MiMedx Group Valuation Multiples

MiMedx Group trades at 1.1x EV/Revenue multiple, and 6.4x EV/EBITDA.

See NTM and 2027E valuation multiples for MiMedx Group

EV / Revenue (LTM)


MiMedx Group Financial Valuation Multiples

As of June 3, 2026, MiMedx Group has market cap of $532M and EV of $390M.

MiMedx Group has a P/E ratio of 22.0x.

LTMLast FY202320242025202620272028
EV/Revenue1.1x0.9x1.2x1.1x0.9x
EV/EBITDA6.4x3.7x9.6x6.1x4.9x
EV/EBIT11.0x5.0x10.5x6.6x6.1x
EV/Gross Profit1.4x1.1x1.5x1.3x1.1x
P/E22.0x10.9x7.9x12.5x10.9x
EV/FCF10.5x5.3x15.7x6.0x5.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified MiMedx Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

MiMedx Group Margins & Growth Rates

MiMedx Group decreased revenue by 36% and EBITDA by 100% in the last fiscal year.

In the most recent fiscal year, MiMedx Group reported gross margin of 83%, EBITDA margin of 25%, and net margin of 12%.

See estimated margins and future growth rates for MiMedx Group

MiMedx Group Margins

Last FY202420252026202720282029
Gross Margin83%83%83%72%
EBITDA Margin25%18%19%0%
EBIT Margin19%17%15%(9%)
Net Margin12%12%12%(3%)
FCF Margin17%18%17%(3%)

MiMedx Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(36%)9%20%(36%)
Gross Profit Growth(44%)8%20%(44%)
EBITDA Growth(100%)59%22%(100%)
EBIT Growth(130%)60%8%(136%)
Net Profit Growth(119%)(37%)15%(119%)
FCF Growth(112%)160%13%(112%)

Data powered by FactSet, Inc. and Morningstar, Inc.

MiMedx Group Operational KPIs

MiMedx Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

MiMedx Group's Rule of 40 is (36%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

MiMedx Group's Rule of X is (90%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for MiMedx Group
LTMLast FY202320242025202620272028
Rule of 40(3%)(36%)---
Bessemer Rule of X(34%)(90%)---
Revenue per Employee-$0.5M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue4%4%4%4%4%
Opex to Revenue70%67%71%66%67%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

MiMedx Group Competitors

MiMedx Group competitors include IBA Group, Nika Pharmaceuticals, Ironwood Pharmaceuticals, XOMA Royalty, Cerus, Cytek Biosciences, Gyre Therapeutics, Eikon Therapeutics, Polynovo and Tectonic Therapeutic.

Most MiMedx Group public comparables operate across Biopharmaceuticals, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IBA Group0.8x0.8x11.4x10.8x
Nika Pharmaceuticals----
Ironwood Pharmaceuticals3.1x2.5x6.6x4.3x
XOMA Royalty10.8x10.1x11.7x35.7x
Cerus2.4x2.3x58.8x40.6x
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Gyre Therapeutics4.2x4.5x35.2x(170.9x)
Eikon Therapeutics--(0.9x)(0.8x)

This data is available for Pro users. Sign up to see all MiMedx Group competitors and their valuation data.

Start Free Trial

Acquisitions by MiMedx Group

MiMedx Group has acquired 1 company to date.

Last acquisition by MiMedx Group was on January 10th 2016. MiMedx Group acquired Stability Biologics for $10M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by MiMedx Group

Stability Biologics
Description
Stability Biologics is a U.S. distributor of human allograft tissues for orthopedic, spine, and wound care procedures, supplying processed bone and soft tissue grafts to over 1,000 surgeons and ambulatory centers nationwide. Based in Louisville, Kentucky, the company partners with tissue banks for sterile, terminally sterilized products like demineralized bone matrix used in spinal fusions. Stability Biologics expanded to dental applications in 2022, maintaining AATB accreditation for quality standards.
HQ CountryUnited States
HQ City
San Antonio, TX
Deal Date10 Jan 2016
Valuation$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all MiMedx Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About MiMedx Group

When was MiMedx Group founded?MiMedx Group was founded in 2008.
Where is MiMedx Group headquartered?MiMedx Group is headquartered in United States.
How many employees does MiMedx Group have?As of today, MiMedx Group has over 837 employees.
Who is the CEO of MiMedx Group?MiMedx Group's CEO is Joseph H. Capper.
Is MiMedx Group publicly listed?Yes, MiMedx Group is a public company listed on Nasdaq.
What is the stock symbol of MiMedx Group?MiMedx Group trades under MDXG ticker.
When did MiMedx Group go public?MiMedx Group went public in 2007.
Who are competitors of MiMedx Group?MiMedx Group main competitors include IBA Group, Nika Pharmaceuticals, Ironwood Pharmaceuticals, XOMA Royalty, Cerus, Cytek Biosciences, Gyre Therapeutics, Eikon Therapeutics, Polynovo, Tectonic Therapeutic.
What is the current market cap of MiMedx Group?MiMedx Group's current market cap is $532M.
What is the current revenue of MiMedx Group?MiMedx Group's last 12 months revenue is $355M.
What is the current revenue growth of MiMedx Group?MiMedx Group revenue growth (NTM/LTM) is (20%).
What is the current EV/Revenue multiple of MiMedx Group?Current revenue multiple of MiMedx Group is 1.1x.
What is the current EBITDA of MiMedx Group?MiMedx Group's last 12 months EBITDA is $61M.
What is MiMedx Group's EBITDA margin?MiMedx Group's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of MiMedx Group?Current EBITDA multiple of MiMedx Group is 6.4x.
What is the current FCF of MiMedx Group?MiMedx Group's last 12 months FCF is $37M.
What is MiMedx Group's FCF margin?MiMedx Group's last 12 months FCF margin is 10%.
What is the current EV/FCF multiple of MiMedx Group?Current FCF multiple of MiMedx Group is 10.5x.
How many companies MiMedx Group has acquired to date?As of June 2026, MiMedx Group has acquired 1 company.
What was the largest acquisition by MiMedx Group?$10M acquisition of Stability Biologics on 10th January 2016 was the largest M&A MiMedx Group has done to date.
What companies MiMedx Group acquired?MiMedx Group acquired Stability Biologics.
In how many companies MiMedx Group has invested to date?MiMedx Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to MiMedx Group

Lists including MiMedx Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial